Conflicting Information on Rheumatoid Arthritis
In previous blog entries in October, November, and December 2004, I linked to articles about Remicade, Methotrexate, and Humira respectively. Article, studies, even a manufacturer stated that certain rheumatoid arthritis (RA)medications could be linked to increased lymphoma risk.
Today, articles seem to change the story - in that famous (??) journal Arthritis & Rheumatism, Swedish researchers say that having longstanding RA makes one 70 times more at risk for contracting lymphoma.
The researchers also looked for an association between lymphoma risk and RA treatment, including methotrexate, anti-malarial agents, oral steroids, non-steroidal anti-inflammatory drugs, and aspirin. But no link association was found.
So what is the story? As usual, talk to your doctor to interpret the rocky road - they are educated to look at your situation and advise you best.
Baecklund E et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis & Rheumatism. 2006; 54(3):692-701.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
